Allogenic blood transfusion may prolong the duration of hospital stays 5 and may adversely affect the outcomes of surgical patients by increasing the risk of surgical site infection and periprosthetic joint infection 6, 7 . Therefore, great effort has been made to reduce the rate of allogenic blood transfusion by implementing various blood conservation strategies to reduce perioperative blood loss 4 .
Identifying patients at increased risk of considerable perioperative blood loss and the need for perioperative blood transfusion is an important step toward establishing an effective blood management strategy 8 . Numerous studies have been performed to identify predictors of transfusion requirement in patients undergoing total joint arthroplasty [9] [10] [11] [12] [13] . However, only the role of preoperative hemoglobin as a predictor of transfusion requirement has been well defined 12 . Few studies have elucidated predictors of blood loss during total joint arthroplasty 14, 15 , and it is not clear which clinical factors affect perioperative blood loss in patients undergoing total joint arthroplasty. The majority of these studies have their own limitations such as using estimated blood loss and showing a relatively small sample size. Therefore, the present study was designed and was carried out to identify predictors of blood loss as well as the transfusion requirement in a large cohort of patients undergoing total joint arthroplasty with calculated blood loss.
Materials and Methods
A fter obtaining approval from the institutional review board, we retrospectively reviewed our electronic total joint arthroplasty database to identify patients undergoing primary total joint arthroplasty from January 2000 to December 2008. Patients who underwent simultaneous bilateral total joint arthroplasty or revision surgery and cases with acquired or congenital bleeding disorders were excluded from the study.
Patients' notes were reviewed to obtain required data including demographics, body mass index (BMI), Charlson Comorbidity Index, type of anesthesia, preoperative autologous blood donation, allogenic blood transfusion, and preoperative and postoperative hematocrit and hemoglobin levels.
The Charlson Comorbidity Index is frequently used to assess underlying comorbidities. The Charlson Comorbidity Index was originally designed to determine the risk of ten-year mortality 16, 17 . We queried our institutional database with use of codes of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) to identify comorbidity items, which have previously been described 17 . Raw scores were then adjusted for age.
During the study period, our institution offered preoperative autologous blood donation to all patients who were scheduling for total joint arthroplasty with a hemoglobin level of no less than 11 g/dL or a hematocrit level of at least 33%. Autologous blood usually is donated within thirty days preoperatively.
Perioperative blood loss was calculated with use of a previously validated formula as described by Rosencher et al. 18 , in which RBC is the acronym for red blood cells and Hct is the abbreviation for hematocrit: The estimated blood volume in milliliters was calculated for women and men separately with use of the formulas: Finally, total blood loss at a hematocrit of 35% was obtained with use of the following equation:
Total blood loss ðmLÞ ¼ ½Total RBC loss ðmLÞ=0:35
The hemoglobin for patients with preoperative autologous blood donation used for the calculation was drawn after the donation.
Statistical Analysis
Separate analyses were performed for patients who had undergone total knee arthroplasty and those who had undergone total hip arthroplasty. Multiple linear regression analyses were performed to identify predictors of perioperative hemoglobin drop to control for potential confounders. Multiple regression models were used to identify predictors of perioperative blood loss. Because data on total blood loss were skewed toward lower values, a generalized linear model with a negative binomial family was used to create the models. A linear link function was used so the model would return intercept and parameter estimates that would be additive. All variables were included in the model (sex, age, Charlson Comorbidity Index, BMI, hypertension, diabetes, anemia, preoperative autologous blood donation, type of anesthesia, and preoperative hemoglobin level). BMI, age, and hemoglobin level were included in the model as continuous variables. Also, logistic regression analysis was performed to identify independent predictors of allogenic blood transfusion. The amount of blood loss and the level of hemoglobin drop were also included in the logistic regression analysis in addition to the above-mentioned variables.
We validated the linear and logistic models with use of 200 bootstrap samples for the total knee arthroplasty and total hip arthroplasty groups. With use of this validation method, we used all of the data to generate the models. Each bootstrap was resampled (with replacement) from the original data set, a model was generated, and then the performance of this model against the original data was tested. The correlation coefficient and the mean squared error for linear regression and the area under the curve for the logistic regression models were calculated.
All analyses were done with use of R 2.15.1 (R Foundation for Statistical Computing, Vienna, Austria) using the rms (regression modeling strategies) package for the logistic regression. In this study, we did not provide a priori hypotheses for any particular variable and the analyses were designed as exploratory with a high likelihood of chance findings, so the critical p value thresholds were adjusted for multiple comparisons. As six multivariate models were created in this study (three models of blood loss, hemoglobin drop, and allogenic blood transfusion for the total hip arthroplasty group and the same three models for the total knee arthroplasty group), using a p value of 0.05, a Bonferroni-adjusted threshold of 0.0083 was used to assess these models. In each model, an adjusted p value of 0.05 divided by the number of variables in each model was considered to be significant.
Source of Funding
No external funds were received for the preparation of this manuscript.
Results
E leven thousand three hundred and seventy-three patients who underwent total joint arthroplasties, including 4769 patients who underwent total knee arthroplasty and 6604 patients who underwent total hip arthroplasty, were evaluated for this study. The mean patient age (and standard deviation) was 66.0 ± 11.2 years for those undergoing total knee arthroplasty and 62.7 ± 13.5 years for those undergoing total hip arthroplasty. Table I demonstrates the characteristics of the study patients. The most frequent comorbidities in the entire cohort were anemia (36.7%), hypertension (32.8%), coronary artery disease (8.7%), diabetes mellitus (7.1%), and chronic obstructive pulmonary disease (6.1%).
Calculated Blood Loss and Hemoglobin Drop
The mean total calculated blood loss (and standard deviation) was 2181.4 ± 931.1 mL for patients undergoing total knee arthroplasty compared with 2363.3 ± 1124.7 mL for patients undergoing total hip arthroplasty. Multivariate analysis indicated that the amount of blood loss was increased by male sex (263.59 mL in patients who underwent total hip arthroplasty and 233.60 mL in patients who underwent total knee arthroplasty), a Charlson Comorbidity Index of >3 (293.99 mL in patients who underwent total hip arthroplasty and 167.96 mL in patients who underwent total knee arthroplasty), and preoperative autologous blood donation (593.51 mL in patients who underwent total hip arthroplasty and 592.30 mL in patients who underwent total knee arthroplasty). In patients who have undergone total hip arthroplasty, multivariate analysis also showed that the amount of blood loss rises by increasing age (3.44 mL per one-year increase) and BMI (12.45 mL per 1-kg/m 2 increase). In patients undergoing total hip arthroplasty, regional anesthesia compared with general anesthesia reduced the amount of blood loss by 326.97 mL (Table II) . Each model was significant overall (p < 0.0001), although the predictive value of both models is poor: the correlation coefficient between prediction and actual observations was 0.12 for patients who underwent total hip arthroplasty and 0.08 for patients who underwent total knee arthroplasty. As each model has ten parameters, a Bonferroni adjustment for multiple comparisons indicates that only p values of 0.005 should be considered significant within each model. The mean postoperative hemoglobin drop (and standard deviation) after the surgery was 3.0 ± 1.2 g/dL for patients undergoing total knee arthroplasty and 3.1 ± 1.6 g/dL for patients undergoing total hip arthroplasty. The results of the multivariate analysis of the amount of hemoglobin drop in patients undergoing total hip arthroplasty and patients undergoing total knee arthroplasty have been summarized in Table III . Compared with a Bonferroni-adjusted threshold of p = 0.0083 for the six multivariate models used in this study, both models are significant (p < 0.0001). For the ten explanatory variables within each model, the Bonferroni-adjusted threshold is p = 0.005. For the total hip arthroplasty regression, the correlation coefficient is 0.22 and the mean squared error is 2.17; after correcting for optimism (200 bootstrap samples), the correlation coefficient is 0.21 and the mean squared error is still 2.17. For the total knee arthroplasty model, the correlation coefficient is 0.28 and the mean squared error is 1.14; after correction for optimism (200 bootstrap samples), the correlation coefficient is still 0.28 and the mean squared error is 1.15. (Table IV) . The predictive power of these models was high; the area under the curve was 0.989 for the total hip arthroplasty model and 0.994 for the total knee arthroplasty model. The correction for optimism with use of 200 bootstrap samples only reduced this performance slightly (0.989 for the total hip arthroplasty model and 0.994 for the total knee arthroplasty model). Each model was significant overall (p < 0.0001). The Bonferroni-adjusted threshold for significance for the twelve parameters in each model was p = 0.004.
Allogenic Blood Transfusion

Discussion
I n spite of advances in surgical and anesthetic techniques, blood loss during total joint arthroplasty can be substantial 2 . The majority of previous studies regarding blood loss in total joint arthroplasty use estimated blood loss, which does not consider ''hidden'' blood loss, including loss due to extravasation into the tissues; residual blood in the joint; and loss due to hemolysis, hematoma formation, or bleeding around the prosthesis 19 . The amount of blood loss in total joint arthroplasty can be substantial. Both the total knee arthroplasty and total hip arthroplasty cohorts had >2 L of calculated blood loss. The calculated blood loss in our study was relatively close to that in the study by Rosencher et al. 18 . They showed that calculated blood loss was significantly higher (1944 mL for patients who underwent total hip arthroplasty and 1934 mL for patients who underwent total knee arthroplasty) compared with estimates (750 mL for patients who underwent total hip arthroplasty and 800 mL for patients who underwent total knee arthroplasty). Sehat et al. 19 showed a mean blood loss of 1510 mL in patients who underwent total hip arthroplasty and 1498 mL in patients who underwent a total knee arthroplasty and a total blood loss from wound drainage of 74% in patients who underwent total hip arthroplasty and 51% in patients who underwent a total knee arthroplasty. The remainder of hidden blood loss was hypothesized to be from considerable bleeding within the soft tissue. In our study, we did not calculate either intraoperative blood loss or hidden blood loss, which is equal to the total blood loss minus the intraoperative and postoperative blood loss. The estimated intraoperative and postoperative blood loss is usually small, consisting of a small proportion of the total blood loss. Although we did not have data on the estimated intraoperative blood loss for patients in our study to compare and to calculate hidden blood loss, considering the large amount of perioperative blood loss in the patients in our study, hidden blood loss was estimated to be large in our patients. As drains are not used routinely at our institution for patients undergoing total joint arthroplasty, we believe that there was considerable bleeding that occurred within the joint and soft tissues postoperatively. The hemoglobin level in our study was also in the range that has been shown in previous studies. The mean hemoglobin drop (and standard deviation) after surgery was 3.0 ± 1.2 g/dL for patients who underwent total knee arthroplasty and 3.1 ± 1.6 g/dL for patients who underwent total hip arthroplasty. The average hemoglobin drop after primary total joint arthroplasty in our study was similar to that in the study by Rosencher et al., which showed a mean hemoglobin drop of 2.8 g/dL 18 .
Consistent with previous studies 12, 20 , we found that preoperative hemoglobin level is a predictor of allogenic blood transfusion. The present study also showed that preoperative autologous blood donation reduces exposure to allogenic blood in patients undergoing lower-extremity total joint arthroplasty as previously described in some studies on patients undergoing total joint arthroplasty 2, 21 . However, it should not be interpreted that preoperative autologous blood donation reduced all sources of blood transfusion or perioperative blood loss. Results of two meta-analyses regarding the effect of preoperative autologous blood donation on the need for blood transfusion showed that preoperative autologous blood donation not only reduces exposure to allogenic blood but also may increase exposure to all red blood cell transfusion in some types of surgical procedures, such as total joint arthroplasty 22, 23 . This happens because preoperative autologous blood donation decreases the preoperative hemoglobin level, which is the most important predictor of perioperative blood transfusion. In the present study, preoperative autologous blood donation was paradoxically identified as an independent predictor for blood loss. Although we do not know the exact reason for this finding, similar to our study, Billote and colleagues also found that in patients undergoing total hip arthroplasty, the estimated mean blood loss (and standard deviation) was higher in autologous blood donors (4991 ± 1042 mL) compared with non-donors (4631 ± 1108 mL) 24 . They suggested that autologous donors were healthier and larger, which biased the study. In our study, we used multivariate analysis to control for the potential confounders. In this model, preoperative autologous blood donation and the Charlson Comorbidity Index were independently associated with increased blood loss while BMI had a negligible effect on perioperative blood loss. Therefore, the significantly higher blood loss in autologous blood donors in our series cannot be explained by the health status and larger body size of donors. Preoperative autologous blood donation has lost favor in many institutions, given the questions about cost and benefit and the use of tranexamic acid. However, although preoperative autologous blood donation is currently offered less frequently at our institution compared with the study period, it is still offered to patients who are scheduling a total joint arthroplasty. On the basis of our cohort, preoperative autologous blood donation is effective in reducing exposure to allogenic blood.
The health status of patients undergoing total joint arthroplasty, which was evaluated by the use of the American Society of Anesthesiologists (ASA) physical status classification system, is a predictor of blood loss 25 . Grosflam et al. reported that being male, receiving general anesthesia, and having an ASA score of 3 can predict greater total blood loss in patients undergoing total hip arthroplasty 25 . In the present study, we used the Charlson Comorbidity Index as an indicator for comorbidities and found that a Charlson Comorbidity Index of >3 is a predictor of blood loss in patients undergoing total knee arthroplasty and patients undergoing total hip arthroplasty. Consistent with previous studies, we showed that perioperative blood loss is greater in male patients [25] [26] [27] [28] . In spite of being a predictor of blood loss, male sex was a protective factor against allogenic blood transfusion. Although many factors may contribute to this finding, it could be explained by the higher level of preoperative hemoglobin in male patients compared with female patients as previously reported 14 .
The role of regional anesthesia in reducing blood loss during total joint arthroplasty has been well defined 29, 30 . When using spinal anesthesia, the blockade of preganglionic sympathetic nerves affects the vascular smooth muscles and leads to vasodilatation of arterioles, arteries, and veins. A generalized loss of tone of the vascular tree secondary to this sympathetic denervation occurs. As a result, peripheral resistance, especially in the region affected by the spinal anesthesia, decreases. Consequently, blood pressure decreases and the vasomotor paralysis and atony result in bleeding that is slow and can be controlled easily 31, 32 . By considering the role of controlled hypotensive anesthesia in reducing intraoperative blood loss, hypertension may increase blood loss, as was found in this study.
The main limitations of this study related to a lack of data on preoperative medications and the use of other blood conservation strategies other than preoperative autologous blood donation and deep vein thrombosis prophylaxis, which can potentially affect the amount of perioperative blood loss. Although tranexamic acid has routinely been used in our institute in recent years, at the time of this study, it was not in routine use and its potential effect on the study results is negligible. We also do not have data on triggers of blood transfusion in the study patients. Generally, a postoperative hemoglobin level of 8 g/dL is considered as a trigger for blood transfusion at our institution. A higher level of hemoglobin may be considered in the presence of hypovolemia symptoms or in patients with underlying cardiac disease. If a patient required blood transfusion, and autologous blood had been collected, autologous blood was typically initially transfused. However, this policy was not followed in all cases.
In conclusion, our study showed that blood loss during total joint arthroplasty is substantial despite using various blood conservation strategies and advances in surgical and anesthetic techniques. Our results showed that although preoperative autologous blood donation reduces exposure to allogenic blood transfusion, it may increase perioperative blood loss. We believe that the results of this study can be used to identify patients who are at an increased risk for large perioperative blood loss and exposure to allogenic blood transfusion during total joint arthroplasty to implement more effective perioperative blood conservation strategies. n 
